BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical's GHG Emissions Data Preview
In 2022, BioMarin Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, BioMarin Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2022 | 2021 | 2020 | 2019 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data. a | 0000000 |
Total Scope 2 | ||||
Location-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Verified Sources Behind BioMarin Pharmaceutical’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore BioMarin Pharmaceutical’s data sources below and access millions more through our Disclosure Search.
Insights into BioMarin Pharmaceutical's Operational Emissions
In 2022, the total operational greenhouse gas (GHG) emissions of BioMarin Pharmaceutical amounted to 23,000 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
0BioMarin Pharmaceutical's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are BioMarin Pharmaceutical's Scope 1 emissions?
In 2022, the total Scope 1 emissions of BioMarin Pharmaceutical were 14,000 metric tons of CO₂ equivalent (tCO₂e). a
Has BioMarin Pharmaceutical reduced its Scope 1 emissions over time?
Since 2020, BioMarin Pharmaceutical's Scope 1 emissions have decreased by 6.67%, reflecting a declining long-term trend in Scope 1 emissions over time. a
Compared to the previous year (2021), BioMarin Pharmaceutical's Scope 1 emissions decreased by 6.67%, highlighting the company's efforts to lower direct emissions from assets it owns or controls. a
What are BioMarin Pharmaceutical's Scope 2 emissions?
In 2022, BioMarin Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 9,000 tCO₂e using the location-based method. a
Has BioMarin Pharmaceutical reduced its Scope 2 emissions over time?
Since 2020, BioMarin Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions ( Location-Based) have increased by 28.57%, reflecting a rising long-term trend in Scope 2 emissions over time. a
Compared to the previous year (2021), BioMarin Pharmaceutical's Scope 2 emissions (Location-Based) rose by 12.5% in 2022, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy a
What methodology does BioMarin Pharmaceutical use for Scope 2 reporting?
In 2022, BioMarin Pharmaceutical reported its Scope 2 emissions using the location-based method. a
BioMarin Pharmaceutical's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
Insights into BioMarin Pharmaceutical’s GHG Emissions Intensity Compared to Industry Peers
In 2022, BioMarin Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 14,000 tCO₂e and total revenues of USD 2,096 millions. This translates into an emissions intensity of 6.68 tCO₂e per millions USD. a
BioMarin Pharmaceutical's Scope 1 Emissions Intensity Compared to Peers
How does BioMarin Pharmaceutical's GHG emissions intensity compare to its peers?
In 2022, BioMarin Pharmaceutical reported a Scope 1 emissions intensity of 6.68 tCO₂e per millions USD. Compared to the peer group median of 2.44 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. a
Where does BioMarin Pharmaceutical rank on GHG emissions intensity within its industry?
In 2022, BioMarin Pharmaceutical ranked 17 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
This places BioMarin Pharmaceutical among the least efficient performers, with one of the highest emissions intensities in its sector. a